Gerresheimer Boston Consulting Group Matrix
Fully Editable
Tailor To Your Needs In Excel Or Sheets
Professional Design
Trusted, Industry-Standard Templates
Pre-Built
For Quick And Efficient Use
No Expertise Is Needed
Easy To Follow
Gerresheimer Bundle
Visual. Strategic. Downloadable.
Gerresheimer’s BCG Matrix peels back the curtain on which product lines are driving growth, which are funding the business, and which are dragging it down. This snapshot hints at strategic moves, but the full BCG Matrix gives you quadrant-by-quadrant placement, data-backed recommendations, and editable Word + Excel files to act on immediately. Purchase the complete report to skip the guesswork and plan your next moves with confidence.
Stars
Pre-fillable syringes (RTF)
Biologics reached about USD 420 billion in 2024 and global pre-fillable syringe (PFS) demand was roughly USD 5.2 billion, driving strong uptake of Gerresheimer’s ready-to-fill formats that combine scale and pharma-grade quality. High switching costs plus regulatory file transfers and device validations create durable share protection. Continued investment in capacity, quality systems and customer onboarding will defend leadership and let RTFs mature into cash cows as growth normalizes.
Auto-injectors and pens
Self-administration is mainstream in specialty meds, and Gerresheimer’s auto-injectors and pens sit in the Stars quadrant as device programs win sticky, high-value contracts; service components now often exceed 20% of deal value (2024 industry benchmarks). The mix skews to higher ASPs and recurring services, supporting premium margins. Double down on innovation, human factors, and lifecycle upgrades to remain first-in-line for new molecules, and keep service teams synchronized with pharma launch calendars.
Advanced sterile vials (ready-to-use)
Advanced sterile vials (ready-to-use) cut fill-finish risk and are high-demand Stars in the >$400bn global biologics market in 2024, making them attractive to CDMOs and pharma. Premium pricing and validated supply chains protect Gerresheimer share and margins. Prioritize investment in capacity, secondary packaging and sterilization technology. Maintain rigorous compliance to keep rivals out.
High-performance glass (low-defect, coated)
High-performance borosilicate vials with anti-delamination coatings and tight specs reduce breakage and delamination, critical for injectables; 2024 production runs reported measurable drops in rejects and faster regulatory audits for leading suppliers. Ongoing capex into furnace upgrades and inline inspection preserves this quality moat in a growing injectable glass segment.
- Elite borosilicate
- Coatings cut delamination
- Tight specs lower rejects
- Capex: furnace + inline inspection
- 2024: smoother regulatory audits
Inhalation devices (DPIs/MDIs platforms)
Chronic respiratory demand remains high—WHO reports ~262 million people with asthma and ~251 million with COPD (2019), underpinning steady inhaler volume; reformulations for low-global-warming-potential propellants add momentum for DPIs/MDIs platforms. Platform devices with proven reliability anchor major accounts; prioritize sustainability redesigns and fast-track validations to stay the default when portfolios switch.
- High prevalence: asthma 262M, COPD 251M (WHO 2019)
- Focus: green propellants and fast validation
- Strategy: sustain reliability to retain large accounts
- Goal: remain default supplier during portfolio transitions
Ready-to-fill PFS, auto-injectors chase USD 420bn biologics market
Gerresheimer’s Stars: ready-to-fill formats and auto-injectors capture 2024 biologics tailwinds (global biologics ~USD 420bn; PFS demand ~USD 5.2bn) with high switching costs and services >20% of deal value, driving premium margins. Invest in capacity, human factors and sterilization tech to convert Stars to future cash cows.
| Product | 2024 metric | Key action |
|---|---|---|
| Ready-to-fill PFS | USD 5.2bn demand | Capex + quality |
| Auto-injectors | Services >20% deal value | HFE + lifecycle |
| Sterile vials | Biologics USD 420bn | Sterilization tech |
What is included in the product
Detailed Word Document
In-depth BCG Matrix review of Gerresheimer's portfolio, with strategic moves for Stars, Cash Cows, Question Marks and Dogs.
Customizable Excel Spreadsheet
One-page Gerresheimer BCG Matrix placing each business unit in a quadrant for quick strategy clarity and action
Cash Cows
Standard vials and ampoules
Standard vials and ampoules are a mature, massive and stable cash cow for Gerresheimer, underpinning roughly €1.5bn group sales in 2024 and generating steady free cash flow. Scale drives cost leadership and margin resilience; keeping OEE high and scrap low is critical, with incremental line upgrades typically paying back in under 18 months. Maintain price discipline over promotional spend to protect cash conversion and EBITDA contribution.
Pharma plastic bottles (HDPE/PET)
OTC and Rx oral solids keep HDPE/PET bottle lines humming in a low-growth market (approx. 1–3% annual growth), delivering predictable volumes and long contracts typically 3–7 years. Efficient molds and scale drive gross margins; lightweighting initiatives can reduce material use by up to 15–20% and widen margins. Minimal selling is required as volumes are contract-backed and repeatable.
Cosmetic glass packaging
Branded beauty is steady with repeat SKUs and reliable reorders that stabilize demand; maintaining furnace utilization above 90% converts fixed costs into cash when production runs full. Optimize SKU mix toward premium finishes, which can command a 20–30% price premium, and tighten batch planning to reduce changeover losses. Protect long-term customer relationships and avoid overspending on short-lived novelty runs that dilute margins.
Droppers, closures, and accessories
Droppers, closures, and accessories bundle naturally with primary containers, supporting Gerresheimer’s focus on integrated solutions; the global pharma closures market showed low-single-digit growth in 2024 while exhibiting high repeat demand from existing customers.
Standardize components and cut SKU complexity to lower OPEX and inventory; prioritize milking the installed base with tight quality controls to protect margin and compliance.
- Tag: low-growth, high-repeat
- Tag: standardize-SKU
- Tag: bundle-with-containers
- Tag: milk-installed-base
- Tag: quality-first
Legacy device components
Legacy device components act as Gerresheimer cash cows, providing stable revenue—accounting for roughly 30% of product sales in 2024—and supporting corporate cash flow; tooling is largely amortized and unit-level margins remain healthy, near mid-teen EBITDA for these lines. Maintain tooling and QA, avoid major redesigns, and harvest cash to fund higher-growth bets in drug delivery and specialty glass.
- Stable revenue: ~30% of 2024 sales
- Margins: mid-teens EBITDA on legacy lines
- Capex: minimal for tooling upkeep
- Strategy: maintain QA/tooling, harvest funds, reinvest in growth
€1.5bn vials, 15-20% cut, beauty +20-30% premium
Standard vials/ampoules: ~€1.5bn sales 2024, high margins, payback <18m.
Oral solids/HDPE: 1–3% growth, lightweighting saves 15–20% material.
Branded beauty: >90% utilization, premium +20–30% price.
Legacy devices: ~30% product sales, mid-teens EBITDA, low capex.
| Item | 2024 |
|---|---|
| Vials | €1.5bn |
| Legacy | 30% sales |
Preview = Final Product
Gerresheimer BCG Matrix
The Gerresheimer BCG Matrix you're previewing is the exact file you'll receive after purchase. No watermarks, no demo placeholders—just a fully formatted, analysis-ready report built for strategic clarity. Once bought, the final document is delivered immediately and is ready to edit, print, or present to your team or clients. Crafted by strategy experts, it slots straight into your planning and decision-making without surprises.
Dogs
Undifferentiated commodity glass SKUs
When specifications are generic and rivals undercut, margins evaporate and unit gross margins for undifferentiated glass SKUs frequently compress to single digits. High volumes do not restore low price realization, so Gerresheimer should exit tail SKUs or consolidate tooling to cut complexity. Redeploy freed capacity toward differentiated, higher-value vial and cartridge runs to protect margin and utilization.
Low-volume custom vanity projects
One-off low-volume vanity projects drain engineering hours and force frequent line changeovers, reducing throughput and raising per-unit costs. Cash returns rarely match the complexity and operational disruption, so trim SKUs or shift retained items to premium pricing to cover costs. Implement stricter go/no-go gates and say no more often to protect core margins.
Aging device variants with declining programs
End-of-life platforms limp along supplying service parts and tie up inventory: industry studies show legacy SKUs can be ~70% of SKU count but generate <20% of revenue, driving inventory carrying costs of roughly 15–25% annually. Plan clear sunset schedules, bundle last-time-buys to capture residual demand and reduce small-batch headaches. Redeploy tooling where ROI > payback threshold or scrap decisively to cut holding costs.
Price-capped tenders with strict lowest-bid wins
Price-capped tenders with strict lowest-bid wins are classic Dogs for Gerresheimer: they soak up manufacturing capacity for thin, often single-digit margins, leaving little room for quality-led upsell and compromising average selling prices (ASPs). Avoid participating unless lines are idle or the contract is strategically essential to retain a key customer; passing preserves ASPs and protects premium portfolio segments. Monitor utilization and margin floors closely in 2024.
Over-engineered features buyers won’t pay for
Over-engineered features that procurement won't fund become Dogs for Gerresheimer; in 2024 Gerresheimer reported group sales of €1.9bn, so non-revenue features that add cost risk margin pressure and reduced ROI. Extra steps slow throughput and raise per-unit costs, hurting margins and delivery times. Remove or repackage as optional modules, keeping the core simple and profitable.
- Focus: core profitable SKUs
- Optional add-ons: shift cost to buyer
- Throughput: eliminate extra steps
- Measure: track contribution margin per SKU
Sunset 70% legacy SKUs: stop dogs, redeploy capacity, lift margins
Dogs are low‑margin, commoditized SKUs that compress gross margins to single digits and drain capacity. Legacy SKUs (~70% of SKUs) generate <20% of revenue and push inventory carrying costs to ~15–25% annually. With 2024 group sales €1.9bn, exit or consolidate tail SKUs, redeploy tooling to vials/cartridges, enforce strict go/no‑go gates and premium pricing for retained items.
| Metric | Value | Action |
|---|---|---|
| Gross margin (undiff SKUs) | Single‑digit % | Exit/price up |
| Legacy SKU share | ~70% of SKUs; <20% revenue | Sunset/scrap |
| Inventory cost | ~15–25% pa | Reduce SKUs |
| 2024 sales | €1.9bn | Redeploy capacity |
Question Marks
Polymer syringes and vials (COP/COC)
Polymer syringes and vials (COP/COC) are a strong fit for sensitive biologics—2024 adoption sits near 20% of parenteral primary packaging versus ~80% glass, with polymer prefilled-syringe demand growing ~10% CAGR outlook to 2029. High growth potential for Gerresheimer warrants investing in stability proofs and big-pharma validations; if pull-through stalls, narrow indications and refocus commercial efforts.
Connected drug delivery (smart caps, sensors)
Connected drug delivery targets a huge pain point—US medication nonadherence costs an estimated 100–300 billion dollars annually—so smart caps and sensors that have shown adherence uplifts of up to ~20% in trials are strategically attractive. Standards and payer reimbursement remained unsettled in 2024, so expect cash burn pre-scale; pilot with top customers and prove outcomes. Double down if reimbursement materializes; divest if engagement stays weak.
Sustainable packaging lines
Sustainable packaging lines face rising 2024 regulatory and brand pressure, while customer willingness to pay remains mixed; early wins (recyclable caps, mono-materials) can cascade into mandatory specs. Build recyclable options and LCA proof points to capture value and document CO2 savings. If margins lag, position sustainable SKUs as add-ons rather than core until cost parity or premium realization.
Contract assembly/CDMO device services
Contract assembly/CDMO device services are a Question Mark for Gerresheimer: pharma outsourcing drives a global CDMO market ~160 billion USD in 2024 with ~8% CAGR, offering big upside, but the field is crowded and requires heavy QA/regulatory investment; Gerresheimer holds low share today while demand grows. Winning lighthouse programs to secure multiyear contracts is critical—either invest in cleanrooms and throughput or remain a niche specialist.
- Market: ~160B USD (2024), ~8% CAGR
- Status: Low share, high-growth
- Strategy: Win lighthouse programs
- Options: Scale cleanrooms/throughput or niche
- Risk: Intense competition, heavy QA costs
Next-gen inhalers for new propellants
Next‑gen inhalers for low‑GWP propellants sit in Question Marks as market shifts toward green propellants accelerate but timing remains uneven across regions; pMDIs still represent roughly half of global inhaler units in 2024.
Technical and validation risks persist, with regulatory pathways and stability data required before scale; co‑development with anchor clients can secure initial wins.
If standards drift away from the platform, pivot platform learnings into existing HFA devices to capture near‑term revenue.
- Market: pMDIs ~50% of units (2024); uneven regulatory timelines
- Risk: tech validation, stability testing, and regulatory approval hurdles
- Action: co‑develop with anchor clients for first wins; pivot learnings to legacy devices if standards change
Polymer PFS 20%, 10% CAGR; CDMO 160B
Polymer PFS/vials: ~20% polymer share (2024) vs ~80% glass; polymer PFS demand ~10% CAGR to 2029 — invest in stability/validation or narrow focus. Connected delivery: US nonadherence USD100–300B; trials show up to ~20% adherence uplift — pilot and prove outcomes. CDMO/prefill: market ~160B USD (2024), ~8% CAGR; win lighthouse contracts or remain niche.
| Segment | 2024 | Growth | Key risk | Action |
|---|---|---|---|---|
| Polymer PFS | 20% share | ~10% CAGR | validation | invest/validate |
| Connected | — | outcome-dependent | reimbursement | pilot |
| CDMO | 160B USD | ~8% CAGR | competition | secure lighthouses |